{'fraction_non_alphanumeric': 0.021256931608133085, 'fraction_numerical': 0.009242144177449169, 'mean_word_length': 5.050279329608938, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Cloning of HSA-GHGKHKNK fusion protein cDNA and its experssion in Pichia pastoris

GHGKHKNK octapeptide has tumoricidal potential mainly due to the amino acid residues of His-Gly-Lys motif inhibits the clone formation, adhesion and invasion of tumor cells. However, its clinical application is limited by its short half-life time in vivo. We used human serum albumin (HSA) fusion technology to fuse GHGKHKNK octapeptide and HSA to prolong half-life time of GHGKHKNK octapeptide and increase its stability. the GHGKHKNK — HSA fusion protein gene was cloned into the secretor type expression vector pPICZaC and subsequently expressed in Pichia pastoris. The supernatant fusion protein was detected by SDS-PAGE and purified with Blue Sepharose 6 Fast Flow chromatography. The clone formation rate of melanoma B16-F10 cell strain and the effect of the octapetide on the expression level of LN-R, ICAM-1 in melanoma B16-F10 cell strain were measured. Results suggested that infusion reaction between GHGKHKNK octapeptide and HSA did not destroy biologic activity of GHGKHKNK octapeptide.